Xarelto® Blood Thinning Medication Causes Uncontrolled Bleeding, New Lawsuit Alleges
According to a recent lawsuit filed in the Philadelphia County Court of Common Pleas (Stuntebeck v. Johnson & Johnson, et al.), the anticoagulant drug, Xarelto® (rivaroxaban), is alleged to cause serious and uncontrolled internal bleeding that might be irreversible, that could result in life-threatening injuries and even death.
The anti-clotting medication Xarelto®, which is marketed by Johnson & Johnson in the U.S. and by Bayer outside the U.S., was approved by the Food and Drug Administration (FDA) in July 2011 for use in patients who recently underwent hip or knee replacement surgery to reduce the risk of blood clots. In November 2011, the FDA expanded the use of Xarelto® for patients with atrial fibrillation (AF) to reduce the risk of stroke. Then in 2012, the FDA expanded the use of Xarelto® for the general treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). According to recent reports, Bayer has been trying to get Xarelto® approved for use in acute coronary syndrome (ACS) patients, but the FDA in February turned them down for the third time.
A lawsuit involving another blood thinning medication, Pradaxa®, recently resulted in a $650 Million settlement to resolve approximately 4,000 Pradaxa® claims. Like Pradaxa®, Xarelto® has no known antidote for uncontrolled bleeding and does not require regular monitoring of blood levels.
The current market for blood thinning medications, including Xarelto®, is estimated to be worth $10 billion. Last year, Xarelto® sales reached $1.3 Billion and Bayer’s Chief Executive, Marijn Dekkers, expects that sales will reach around 3.5 Billion Euros annually.
“We will fight for the rights of individuals who allege to have experienced serious and life-threatening injuries after using Xarelto®,” says Roger Denton of Schlichter, Bogard & Denton, LLP. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have been injured after using Xarelto®.
About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications and unsafe medical devices, including but not limited to: In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100), In re: NuvaRing® Products Liability Litigation (MDL 1964), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909), and In re: Ortho Evra® Products Liability Litigation (MDL 1742).
The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.
If you or a loved one has suffered serious injuries after using Xarelto®, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys with these types of cases are invited to contact an attorney at the firm to explore this opportunity.
The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.